用于GLP-1药物治疗的针手腕带的抗效果与恶心相关的恶心
Florencia Ziemke1, Soufiane Belarj1, Jem Esguerra1
1Evexia Medical, Jupiter, FL, USA.
Obesity pillars
|June 9, 2025
概括
针治疗腕带 (ACW) 在服用GLP-1受体激活剂 (GLP-1a) 的患者中有效降低了恶心. 超过80%的恶心发作得到了缓解,为控制这种常见的副作用提供了无药的解决方案.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 胃肠病学 胃肠病学
- 综合医学是一个整体的医学.
背景情况:
- 恶心是葡萄糖样-1受体激动剂 (GLP-1a) 的常见副作用,影响治疗坚持.
- 目前针对GLP-1a诱导的恶心的管理策略往往不足,可能会破坏治疗.
- 海-Band®针手腕带 (ACW) 是一种无药,经FDA批准的设备,用于各种恶心类型.
研究的目的:
- 评估针治疗腕带 (ACW) 在与GLP-1受体激活剂 (GLP-1a) 相关的恶心的成年人中抗效.
- 评估ACW作为一种潜在的自我管理的非药物干预措施,用于GLP-1a相关的恶心.
主要方法:
- 一项单臂,开放标签,前性干预研究对31名非怀孕的成年人进行,使用GLP-1a (西马格卢提德或提泽帕提德) 与恶心.
- 参与者在恶心开始时使用了ACW,并被监测了4周,评估了恶心的频率,ACW的使用和症状的缓解.
- 排除标准包括没有恶心,最近使用抗药,以及其他引起恶心的情况.
主要成果:
- 在参与者中记录了超过359次恶心发作,超过80%的队列每周报告恶心.
- 在所有恶心发作中使用ACW,超过80%的这些发作实现了恶心缓解.
- 在大多数发作中,在5-20分钟内观察到恶心缓解,在整个研究中有效性一致.
结论:
- 这项试点研究表明,针手腕带 (ACW) 是一种安全的,无毒的选择,用于管理GLP-1a相关的恶心.
- ACW在减少恶心发作方面表现出超过80%的有效性,为许多参与者提供了快速缓解.
- ACW可以作为一种有价值的第一线干预措施,以改善GLP-1a用户的患者福祉和治疗坚持.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
152
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
152
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
233
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
233
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
166
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
166
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
179
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
179
Dipeptidyl Peptidase 4 Inhibitors
177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302


